Is ADMA or ACET more profitable?

ADMA Biologics has a net margin of 32.98% compared to Adicet Bio's net margin of 0.00%. ADMA Biologics' return on equity of 40.17% beat Adicet Bio's return on equity. Company Net Margins Return on Equity Return on Assets ADMA Biologics 32.98% 40.17% 26.97% Adicet Bio N/A -74.90% -60.87%

Does the media refer more to ADMA or ACET?

In the previous week, Adicet Bio had 1 more articles in the media than ADMA Biologics. MarketBeat recorded 7 mentions for Adicet Bio and 6 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.17 beat Adicet Bio's score of 0.52 indicating that ADMA Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adicet Bio 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is SABS or ACET more profitable?

SAB Biotherapeutics' return on equity of -6.74% beat Adicet Bio's return on equity. Company Net Margins Return on Equity Return on Assets SAB Biotherapeutics N/A -6.74% -6.06% Adicet Bio N/A -74.90% -60.87%

Does the media favor SABS or ACET?

In the previous week, Adicet Bio had 5 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 7 mentions for Adicet Bio and 2 mentions for SAB Biotherapeutics. SAB Biotherapeutics' average media sentiment score of 1.77 beat Adicet Bio's score of 0.52 indicating that SAB Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SAB Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Adicet Bio 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, IMRX or ACET?

Immuneering is trading at a lower price-to-earnings ratio than Adicet Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immuneering N/A N/A -$56.03M -$1.04 N/A Adicet Bio N/A N/A -$116.80M -$11.45 N/A

Is IMRX or ACET more profitable?

Immuneering's return on equity of -27.15% beat Adicet Bio's return on equity. Company Net Margins Return on Equity Return on Assets Immuneering N/A -27.15% -25.75% Adicet Bio N/A -74.90% -60.87%

Does the media refer more to IMRX or ACET?

In the previous week, Adicet Bio had 2 more articles in the media than Immuneering. MarketBeat recorded 7 mentions for Adicet Bio and 5 mentions for Immuneering. Adicet Bio's average media sentiment score of 0.52 beat Immuneering's score of -0.27 indicating that Adicet Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immuneering 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Adicet Bio 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is CLLS or ACET more profitable?

Adicet Bio has a net margin of 0.00% compared to Cellectis' net margin of -102.34%. Adicet Bio's return on equity of -74.90% beat Cellectis' return on equity. Company Net Margins Return on Equity Return on Assets Cellectis -102.34% -94.19% -21.34% Adicet Bio N/A -74.90% -60.87%

Does the media prefer CLLS or ACET?

In the previous week, Adicet Bio had 3 more articles in the media than Cellectis. MarketBeat recorded 7 mentions for Adicet Bio and 4 mentions for Cellectis. Cellectis' average media sentiment score of 0.75 beat Adicet Bio's score of 0.52 indicating that Cellectis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectis 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adicet Bio 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is ACET or IRD more profitable?

Adicet Bio has a net margin of 0.00% compared to Opus Genetics' net margin of -1,091.82%. Adicet Bio's return on equity of -74.90% beat Opus Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Adicet Bio N/A -74.90% -60.87% Opus Genetics -1,091.82% -338.88% -150.13%

Does the media favor ACET or IRD?

In the previous week, Adicet Bio and Adicet Bio both had 7 articles in the media. Opus Genetics' average media sentiment score of 1.26 beat Adicet Bio's score of 0.52 indicating that Opus Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adicet Bio 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Opus Genetics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Adicet Bio (ACET) Competitors

$9.06 +0.05 (+0.55%)

As of 08/28/2026 04:00 PM Eastern

Compare

ACET vs. ADMA, SABS, IMRX, CLLS, and IRD

Should you buy Adicet Bio stock or one of its competitors? Adicet Bio's main competitors and comparable companies include ADMA Biologics (ADMA), SAB Biotherapeutics (SABS), Immuneering (IMRX), Cellectis (CLLS), and Opus Genetics (IRD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Adicet Bio compare to ADMA Biologics?

ADMA Biologics (NASDAQ:ADMA) and Adicet Bio (NASDAQ:ACET) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

ADMA Biologics has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market. Comparatively, Adicet Bio has a beta of 1.6, indicating that its stock price is 60% more volatile than the broader market.

75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 83.9% of Adicet Bio shares are held by institutional investors. 3.9% of ADMA Biologics shares are held by company insiders. Comparatively, 3.4% of Adicet Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

ADMA Biologics currently has a consensus price target of $18.67, indicating a potential upside of 99.86%. Adicet Bio has a consensus price target of $46.80, indicating a potential upside of 416.56%. Given Adicet Bio's stronger consensus rating and higher possible upside, analysts plainly believe Adicet Bio is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Adicet Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

ADMA Biologics has a net margin of 32.98% compared to Adicet Bio's net margin of 0.00%. ADMA Biologics' return on equity of 40.17% beat Adicet Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.98%	40.17%	26.97%
Adicet Bio	N/A	-74.90%	-60.87%

In the previous week, Adicet Bio had 1 more articles in the media than ADMA Biologics. MarketBeat recorded 7 mentions for Adicet Bio and 6 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.17 beat Adicet Bio's score of 0.52 indicating that ADMA Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adicet Bio	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

ADMA Biologics has higher revenue and earnings than Adicet Bio. Adicet Bio is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17M	4.10	$146.93M	$0.70	13.34
Adicet Bio	N/A	N/A	-$116.80M	-$11.45	N/A

Summary

ADMA Biologics beats Adicet Bio on 9 of the 16 factors compared between the two stocks.

How does Adicet Bio compare to SAB Biotherapeutics?

SAB Biotherapeutics (NASDAQ:SABS) and Adicet Bio (NASDAQ:ACET) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

SAB Biotherapeutics currently has a consensus price target of $12.00, indicating a potential upside of 216.62%. Adicet Bio has a consensus price target of $46.80, indicating a potential upside of 416.56%. Given Adicet Bio's stronger consensus rating and higher probable upside, analysts clearly believe Adicet Bio is more favorable than SAB Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Adicet Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

SAB Biotherapeutics has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market. Comparatively, Adicet Bio has a beta of 1.6, suggesting that its stock price is 60% more volatile than the broader market.

In the previous week, Adicet Bio had 5 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 7 mentions for Adicet Bio and 2 mentions for SAB Biotherapeutics. SAB Biotherapeutics' average media sentiment score of 1.77 beat Adicet Bio's score of 0.52 indicating that SAB Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SAB Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Adicet Bio	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

SAB Biotherapeutics' return on equity of -6.74% beat Adicet Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	N/A	-6.74%	-6.06%
Adicet Bio	N/A	-74.90%	-60.87%

SAB Biotherapeutics has higher revenue and earnings than Adicet Bio. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than Adicet Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	$1.32M	261.25	$13.27M	-$1.30	N/A
Adicet Bio	N/A	N/A	-$116.80M	-$11.45	N/A

7.8% of SAB Biotherapeutics shares are held by institutional investors. Comparatively, 83.9% of Adicet Bio shares are held by institutional investors. 7.4% of SAB Biotherapeutics shares are held by company insiders. Comparatively, 3.4% of Adicet Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

SAB Biotherapeutics beats Adicet Bio on 8 of the 15 factors compared between the two stocks.

How does Adicet Bio compare to Immuneering?

Immuneering (NASDAQ:IMRX) and Adicet Bio (NASDAQ:ACET) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

Immuneering has a beta of 0.43, indicating that its stock price is 57% less volatile than the broader market. Comparatively, Adicet Bio has a beta of 1.6, indicating that its stock price is 60% more volatile than the broader market.

67.7% of Immuneering shares are held by institutional investors. Comparatively, 83.9% of Adicet Bio shares are held by institutional investors. 14.9% of Immuneering shares are held by company insiders. Comparatively, 3.4% of Adicet Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Adicet Bio had 2 more articles in the media than Immuneering. MarketBeat recorded 7 mentions for Adicet Bio and 5 mentions for Immuneering. Adicet Bio's average media sentiment score of 0.52 beat Immuneering's score of -0.27 indicating that Adicet Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immuneering	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Adicet Bio	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Immuneering's return on equity of -27.15% beat Adicet Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-27.15%	-25.75%
Adicet Bio	N/A	-74.90%	-60.87%

Immuneering is trading at a lower price-to-earnings ratio than Adicet Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.04	N/A
Adicet Bio	N/A	N/A	-$116.80M	-$11.45	N/A

Immuneering presently has a consensus price target of $17.50, suggesting a potential upside of 250.70%. Adicet Bio has a consensus price target of $46.80, suggesting a potential upside of 416.56%. Given Adicet Bio's higher probable upside, analysts clearly believe Adicet Bio is more favorable than Immuneering.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Adicet Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Immuneering and Adicet Bio tied by winning 7 of the 14 factors compared between the two stocks.

How does Adicet Bio compare to Cellectis?

Cellectis (NASDAQ:CLLS) and Adicet Bio (NASDAQ:ACET) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Cellectis currently has a consensus target price of $7.00, suggesting a potential upside of 105.88%. Adicet Bio has a consensus target price of $46.80, suggesting a potential upside of 416.56%. Given Adicet Bio's higher possible upside, analysts plainly believe Adicet Bio is more favorable than Cellectis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Adicet Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

63.9% of Cellectis shares are held by institutional investors. Comparatively, 83.9% of Adicet Bio shares are held by institutional investors. 16.4% of Cellectis shares are held by insiders. Comparatively, 3.4% of Adicet Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Cellectis has higher revenue and earnings than Adicet Bio. Cellectis is trading at a lower price-to-earnings ratio than Adicet Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$79.59M	4.29	-$67.59M	-$0.65	N/A
Adicet Bio	N/A	N/A	-$116.80M	-$11.45	N/A

Cellectis has a beta of 2.91, suggesting that its stock price is 191% more volatile than the broader market. Comparatively, Adicet Bio has a beta of 1.6, suggesting that its stock price is 60% more volatile than the broader market.

In the previous week, Adicet Bio had 3 more articles in the media than Cellectis. MarketBeat recorded 7 mentions for Adicet Bio and 4 mentions for Cellectis. Cellectis' average media sentiment score of 0.75 beat Adicet Bio's score of 0.52 indicating that Cellectis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectis	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adicet Bio	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Adicet Bio has a net margin of 0.00% compared to Cellectis' net margin of -102.34%. Adicet Bio's return on equity of -74.90% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectis	-102.34%	-94.19%	-21.34%
Adicet Bio	N/A	-74.90%	-60.87%

Summary

Cellectis beats Adicet Bio on 8 of the 15 factors compared between the two stocks.

How does Adicet Bio compare to Opus Genetics?

Adicet Bio (NASDAQ:ACET) and Opus Genetics (NASDAQ:IRD) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

Adicet Bio has a beta of 1.6, indicating that its share price is 60% more volatile than the broader market. Comparatively, Opus Genetics has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market.

83.9% of Adicet Bio shares are owned by institutional investors. Comparatively, 15.0% of Opus Genetics shares are owned by institutional investors. 3.4% of Adicet Bio shares are owned by insiders. Comparatively, 11.7% of Opus Genetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Adicet Bio currently has a consensus price target of $46.80, indicating a potential upside of 416.56%. Opus Genetics has a consensus price target of $10.69, indicating a potential upside of 189.76%. Given Adicet Bio's higher possible upside, equities analysts clearly believe Adicet Bio is more favorable than Opus Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adicet Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.89

In the previous week, Adicet Bio and Adicet Bio both had 7 articles in the media. Opus Genetics' average media sentiment score of 1.26 beat Adicet Bio's score of 0.52 indicating that Opus Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adicet Bio	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Opus Genetics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Opus Genetics has higher revenue and earnings than Adicet Bio. Opus Genetics is trading at a lower price-to-earnings ratio than Adicet Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adicet Bio	N/A	N/A	-$116.80M	-$11.45	N/A
Opus Genetics	$14.20M	21.48	-$49.59M	-$1.35	N/A

Adicet Bio has a net margin of 0.00% compared to Opus Genetics' net margin of -1,091.82%. Adicet Bio's return on equity of -74.90% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adicet Bio	N/A	-74.90%	-60.87%
Opus Genetics	-1,091.82%	-338.88%	-150.13%

Summary

Adicet Bio and Opus Genetics tied by winning 7 of the 14 factors compared between the two stocks.

Get Adicet Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACET and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACET vs. The Competition

Export

Metric	Adicet Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$84.82M	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-0.79	11.62	273.16	25.45
Price / Sales	N/A	1,295.88	605.00	76.62
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	0.71	16.53	12.98	6.14
Net Income	-$116.80M	-$22.80M	$3.48B	$348.86M
7 Day Performance	-1.41%	-0.31%	0.13%	-0.80%
1 Month Performance	N/A	9.80%	7.08%	4.13%
1 Year Performance	-21.35%	55.66%	24.67%	15.17%

Adicet Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACET Adicet Bio	3.7861 of 5 stars	$9.06 +0.6%	$46.80 +416.6%	-21.4%	$84.82M	N/A	N/A	90	News Coverage Analyst Downgrade Short Interest Decrease Gap Up
ADMA ADMA Biologics	3.6607 of 5 stars	$9.55 -2.9%	$18.67 +95.5%	-45.9%	$2.20B	$510.17M	13.64	530
SABS SAB Biotherapeutics	3.0653 of 5 stars	$3.62 -4.2%	$12.00 +231.5%	+82.2%	$343.93M	N/A	N/A	140
IMRX Immuneering	3.2706 of 5 stars	$5.18 -2.3%	$17.50 +237.8%	-13.2%	$342.89M	N/A	N/A	60	Analyst Forecast
CLLS Cellectis	1.9936 of 5 stars	$3.19 -6.2%	$7.00 +119.4%	+32.3%	$341.66M	$79.59M	N/A	290	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACET) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adicet Bio (ACET) Competitors

ACET vs. ADMA, SABS, IMRX, CLLS, and IRD

How does Adicet Bio compare to ADMA Biologics?

Summary

How does Adicet Bio compare to SAB Biotherapeutics?

Summary

How does Adicet Bio compare to Immuneering?

Summary

How does Adicet Bio compare to Cellectis?

Summary

How does Adicet Bio compare to Opus Genetics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACET vs. The Competition

Adicet Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adicet Bio (ACET) Competitors

ACET vs. ADMA, SABS, IMRX, CLLS, and IRD

How does Adicet Bio compare to ADMA Biologics?

Which has more volatility and risk, ADMA or ACET?

Do insiders and institutionals have more ownership in ADMA or ACET?

Do analysts prefer ADMA or ACET?

Is ADMA or ACET more profitable?

Does the media refer more to ADMA or ACET?

Which has preferable earnings & valuation, ADMA or ACET?

Summary

How does Adicet Bio compare to SAB Biotherapeutics?

Do analysts recommend SABS or ACET?

Which has more risk & volatility, SABS or ACET?

Does the media favor SABS or ACET?

Is SABS or ACET more profitable?

Which has stronger earnings & valuation, SABS or ACET?

Do insiders and institutionals believe in SABS or ACET?

Summary

How does Adicet Bio compare to Immuneering?

Which has more risk & volatility, IMRX or ACET?

Do insiders & institutionals hold more shares of IMRX or ACET?

Does the media refer more to IMRX or ACET?

Is IMRX or ACET more profitable?

Which has preferable earnings and valuation, IMRX or ACET?

Do analysts rate IMRX or ACET?

Summary

How does Adicet Bio compare to Cellectis?

Do analysts rate CLLS or ACET?

Do institutionals and insiders hold more shares of CLLS or ACET?

Which has stronger valuation and earnings, CLLS or ACET?

Which has more volatility & risk, CLLS or ACET?

Does the media prefer CLLS or ACET?

Is CLLS or ACET more profitable?

Summary

How does Adicet Bio compare to Opus Genetics?

Which has more volatility and risk, ACET or IRD?

Do insiders and institutionals believe in ACET or IRD?

Do analysts prefer ACET or IRD?

Does the media favor ACET or IRD?

Which has stronger valuation & earnings, ACET or IRD?

Is ACET or IRD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACET vs. The Competition

Adicet Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools